Phio Pharmaceuticals(PHIO) - 2024 Q4 - Annual Results

Exhibit 99.1 Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3 Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-March 31, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more ef ...